Rigel Pharmaceuticals (RIGL)
(Real Time Quote from BATS)
$0.92 USD
+0.01 (1.38%)
Updated May 28, 2024 10:38 AM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Brokerage Reports
Rigel Pharmaceuticals, Inc. [RIGL]
Reports for Purchase
Showing records 1 - 20 ( 112 total )
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2023 Results; Heme-Onc Asset Revenues Continue to Climb; Commercialization Plan Laid Out For GAVRETO
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
GAVRETO Joins Rigel''s Roster of Marketed Drugs Following Asset Acquisition
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Continued Pipeline Progress and Commercial Revenue Growth Signal Optimistic Outlook for 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rigel CONNECTs Forces Through New Collaboration in Glioma
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Flurry of Encouraging Presentations Across Rezlidhia and Tavalisse at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rigel and MD Anderson Team Up to Broaden REZLIDHIA''s Reach Across Hematologic Cancers
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q23 Results; Shares Trading at 1x Projected 2024 Price to Sales Early in Commercial Phases; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
COVID-19 Program Updates As Clinical Development Priority Moving Forward Remains On Heme-Onc
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q23 Results; Tavalisse Captures New Patients in Earlier Lines of Therapy; Rezlidhia New Traction Continues
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
1Q23 Results; Tavalisse Continues to Ride the Revenue Wave; Rezlidhia Sales Gain Traction
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2022 Results; Tavalisse Blocking and Tackling; Rezlidhia Impresses Out of the Gate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tavalisse Beats; Rezlidhia Sales Up and Running; Time For New Clinical Developments
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Rezlidhia Launches in the U.S. With Confirmed Pricing Strategy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
First Patient Dosed in Phase 1b Evaluating R289 in Lower Risk MDS; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Christmas Comes Early; Welcome REZLIDHIA to the Sales Bag; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
3Q22 Results; Making Strides in Olutasidenib Development; Further Clinical Updates Forthcoming at ASH
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Tavalisse Misses in COVID-19 Phase 3 Study; Thesis Unaltered Based on Key Contributors; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Strategic Moves With No Surprise from FDA; Opportunities Remain Status Quo
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
Olutasidenib Nicely Fits the Bill for a Deepening Heme- Onc Focused Portfolio; Price Target Increased to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Rigel Pharmaceuticals, Inc.
Industry: Medical - Drugs
2Q22 Results; Tavalisse Traction Continues As Well As New Commercialization Opportunity.
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J